{"entity":{"id":"nct06332274","kind":"trial","name":"tislelizUMaB in canceR Patients With molEcuLar residuaL Disease","aka":["UMBRELLA"],"tldr":"A phase 3 trial of tislelizumab in pancreatic cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.","summary":"tislelizUMaB in canceR Patients With molEcuLar residuaL Disease is a phase 3, randomised interventional study registered as NCT06332274 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 717 participants, started 2025-04-16 and due to reach its primary completion in 2029-04. Interventions recorded: Tislelizumab; Blood sampling; Placebo. Conditions listed: Cancer; Lung Cancer; Colo-rectal Cancer; Pancreas Cancer; Soft Tissue Sarcoma. Primary outcome: Efficacy of tislelizumab compared to placebo as measured by DFS (Disease-free survival). Pancreatic eligibility wording from the registry: \"Histology: TNM stage II-III NSCLC, Stage II-III colorectal cancer, stage I-III pancreatic cancer, grade 3 limb or trunk wall soft-tissue sarcoma\". Sites: France. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06332274","url":"https://clinicaltrials.gov/study/NCT06332274"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["tislelizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06332274","phase":"3","setting":"tislelizUMaB in canceR Patients With molEcuLar residuaL Disease","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","enrolled":717,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06332274/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}